From October 28 to November 1, 2024, the FDA conducted a rigorous on-site inspection of InnoStar Nantong’s facilities, quality management, data integrity, and experimental protocols. This marks InnoStar Nantong facility passed the first FDA GLP inspection successfully，complementing its existing accreditations from NMPA(China) and the OECD. This achievement positions InnoStar Nantong facility among a select group of CROs globally to hold this trio of internationally recognized certifications, enabling seamless support for multi-regional drug development programs under a unified quality framework.
InnoStar is a full-service Contract Research Organization (CRO) offering integrated solutions spanning early-stage drug screening, non-clinical PK/PD/toxicity studies, and clinical translation.
Scan the QR code
Subscription to our Wechat account
